Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial
Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial
This is a follow-up study to investigate the long-term safety and explore efficacy of
 SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and
 completed the initial stage of the Phase I trial (NCT04037345 ) will be followed-up until 60
 months.
The subjects will be followed up at 6-month, 12-month, 24-month, 36-month, 48-month and
 60-month after the initial administration of SMUP-IA-01.
Inclusion Criteria:

 1. Subject who completed the safety and explore efficacy evaluations in SMUP-IA-01 Phase
 I clinical trial.

 2. Subjects who have been treated with either SMUP-IA-01 at least 6 months ago.

 3. Subjects who voluntarily decided to participate and signed the consent form after
 receiving explanations on the clinical trial.

 Exclusion Criteria:

 1. Subjects who were not enrolled in phase 1 clinical trial of SMUP-IA-01 for assessing
 safety and explore efficacy.

 2. Other subjects, excluding those listed above, who were deemed unsuitable by the PI